Company ProfilePremium

Alterity Therapeutics Limited

Company Profile Analysis

Ticker: ATH.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Alterity Therapeutics Limited - Company showcase

Year Founded & Workforce

1997

Alterity Therapeutics Limited logo

Alterity Therapeutics Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Alterity Therapeutics Limited Overview

Alterity is a single-asset, late-clinical-stage neurology biotech built on the "metal hypothesis" of neurodegeneration that its predecessor Prana Biotechnology pioneered. Its lead candidate, ATH434, is an oral, brain-penetrant small molecule designed as an iron chaperone that redistributes excess labile iron and inhibits alpha-synuclein aggregation. In 2025, ATH434 produced positive results in a randomised, double-blind, placebo-controlled Phase 2 trial in Multiple System Atrophy (MSA) — a rare, rapidly fatal Parkinsonian disorder with no approved disease-modifying therapy — and in an open-label study in advanced MSA. In June 2026 the FDA End-of-Phase 2 meeting aligned on a single ~200-patient pivotal Phase 3 using modified UMSARS Part I, which together with confirmatory evidence could support approval. With A$37.3M cash at 30 June 2026, Fast Track and Orphan designations, and new composition-of-matter protection to 2045, Alterity is positioned as one of the more advanced disease-modifying MSA programs globally, but remains pre-revenue and capital-dependent.


Company's own description. Alterity describes itself as a clinical-stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases, focused on disease-modifying therapies for MSA and related Parkinsonian disorders and preparing to initiate a Phase 3 pivotal trial in MSA; it also cites a broad drug discovery platform generating patentable chemical compounds (FY2026 20-F filing release, 31 Aug 2026; EGM release 29 May 2026).

Independent characterisation. Alterity is a pre-revenue drug developer whose economic value rests almost entirely on ATH434 in MSA. Its "revenue" is bank interest — A$1,716,656 in FY2026, up 284.7% on higher cash balances (FY2026 Appendix 4E). Non-dilutive funding comes from the Australian R&D Tax Incentive (A$3.6M recognised in FY2026; A$3.98M refund received July 2026). The business model is classic biotech: fund development through equity (A$40M Feb 2025 and A$20M Sep 2025 placements), then either partner/license ATH434 or commercialise in an orphan market. Management has been engaged in discussions with multiple pharmaceutical companies about strategic collaborations (Q3 FY2026 4C).

Strategy

Strategic themes (FY2026 Chairman's letter and releases): (1) initiate the Phase 3 trial of ATH434 in MSA — the "central operational objective for FY2027", with trial activities by end of CY2026; (2) manage capital carefully and preserve strategic options; (3) evaluate partnering, licensing and other strategic opportunities alongside funding options; (4) broaden institutional engagement in Australia and the US (rationale for the 1:50 consolidation); (5) extend ATH434 into larger indications such as Parkinson's disease, supported by the 2045 patent.

Guidance: No financial guidance; operational guidance is Phase 3 initiation by end of CY2026.

Product Portfolio

AssetDescription & capabilitiesIndication / targetStatus (Oct 2026)Regulatory designationsPricing

ATH434 (oral; mesylate salt)

Small-molecule iron chaperone; designed to reduce labile iron accumulation and inhibit alpha-synuclein aggregation; brain-penetrant

Multiple System Atrophy

Phase 3-ready; FDA-aligned pivotal design (~200 patients, modified UMSARS Part I primary endpoint, 50 mg twice daily); trial activities targeted to begin by end of CY2026; first registrational GMP batch produced

US Fast Track; US and EU Orphan Drug

Not disclosed; company presentation cited ~US$2.4B peak sales potential (H2 2025 presentation, via Quartr)

ATH434

Same molecule

Parkinson's disease and other neurodegenerative disorders

Preclinical/strategic option; new patent cited as supporting broader investment

——

ATH434-201 (completed)

Randomised, double-blind, placebo-controlled Phase 2, 52 weeks; 50 mg cohort ~46% relative treatment effect on UMSARS Part I at week 52; MuSyCA analysis 41% relative effect

Early MSA

Completed; positive topline Jan 2025

——

ATH434-202 (completed)

Open-label Phase 2 in advanced MSA (safety, efficacy, target engagement)

Advanced MSA

Positive data 2025

——

bioMUSE

Natural history / biomarker study with Vanderbilt University Medical Center; neuroimaging published

MSA

Supports endpoint/biomarker strategy

——

Discovery platform

Library of novel compounds from metal-protein attenuation chemistry (legacy of PBT program)

Major neurodegenerative indications

Research

——

PBT2 (legacy)

Earlier-generation compound; later explored as antimicrobial

Legacy

Non-core

——

Financial Narrative

Primary sources: Appendix 4E reports FY2022–FY2026 (ASX/SEC 6-K), FY2026 Form 20-F, H1 FY2026 6-K, quarterly 4Cs.

Income statement (A$ M):

FY2021 comparison: revenue A$20,676; net loss A$15,309,353 (FY2022 Appendix 4E). Five-year revenue CAGR is not meaningful (interest only). EBITDA ≈ operating loss (depreciation immaterial; not separately verified).

Half-year detail H1 FY2026 (6 months to 31 Dec 2025, A$ M): revenue 0.91; R&D tax incentive 2.80; R&D expense 7.84; G&A 5.12 (incl. 2.22 share-based payments); net loss 9.62 (+34% YoY) (H1 FY2026 6-K via Stock Titan).

Balance sheet (A$ M):

Notes: FY2026 NTA per share (19.56c) is post 1:50 consolidation; FY2025 comparative restated to 22.94c on the same basis. Implied FY2026 net tangible assets ≈ A$42.5M (19.56c × 217.5M shares — derived). Total equity at 31 Dec 2025 was A$54.27M (H1 FY2026). No borrowings are disclosed; net debt is negative (net cash = cash).

Cash flow (A$ M):

FY2026 quarterly operating outflows: Q2 A$5.28M; Q4 A$7.17M (quarterly 4Cs). FY2026 investing flows immaterial (Q3 4C).

Ratios. ROE (FY2026, net loss / implied closing NTA ≈ A$42.5M) ≈ −55% (derived); ROA, ROIC, interest coverage, asset turnover, net debt/EBITDA and cash conversion cycle are not meaningful. Debt/equity: 0.

Commentary. The loss profile tracks clinical intensity. FY2024's A$19.1M loss reflected running two Phase 2 trials; FY2025 fell to A$12.1M as trials completed and tax incentives/interest offset spend; FY2026 nearly doubled to A$23.4M as Phase 3 preparation (CMC scale-up, GMP registrational batch, regulatory work) and G&A (including share-based payments after board changes) increased. Cash nonetheless rose from A$12.6M (FY2024) to A$37.3M (FY2026) because of A$60M of placements in 2025. On FY2026 operating burn of ~A$22.5M, the year-end cash plus the A$3.98M July refund implies roughly 18–20 months of runway at current spend — but a ~200-patient global Phase 3 will raise burn substantially, so the company is not funded through Phase 3 readout without partnering or new equity.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityDomicileOwnershipRole

Alterity Therapeutics Limited

Australia

Parent (listed)

Holding, R&D sponsor, IP owner

Alterity Therapeutics Inc.

United States

100%

US operations / clinical-regulatory presence

Alterity Therapeutics UK Limited

United Kingdom

100%

UK/European activities

Revenue by Segment

SegmentFY2024FY2025FY2026

Neurodegenerative drug development — revenue (AUD Mn)

0.270.451.72

Neurodegenerative drug development — net loss (AUD Mn)

-19.12-12.15-23.40

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue — interest income (AUD Mn)

0.0030.0160.270.451.72

Gross profit (AUD Mn)

00000

Loss before income tax (AUD Mn)

—-13.70-19.08——

Net loss after tax (AUD Mn)

-12.85-13.81-19.12-12.15-23.40

R&D tax incentive other income (AUD Mn)

————3.6

YoY change in net loss (%)

-16.17.538.5-36.592.6

Dividends per share (A$ cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD Mn)

—15.7712.6433.1637.32

Net assets / total equity (AUD Mn)

—22.8113.80——

Net tangible assets per share (A$ cents, as reported)

1.480.940.270.4619.56

Total debt (AUD Mn)

00000

Goodwill & intangibles (AUD Mn)

00000

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

———-11.5-22.52

Capex (AUD Mn)

————0

Free cash flow (AUD Mn)

———-11.5-22.52

Financing cash flow (AUD Mn)

————19.13

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Key Financials

MetricQ2 FY2026Q3 FY2026Q4 FY2026

Cash at quarter end (AUD Mn)

49.2044.5337.32

Region revenue (AUD Mn)

Region revenue (AUD Mn)FY2024FY2025FY2026

Australia — interest income (AUD Mn, total group)

0.270.451.72

Americas (AUD Mn)

000

EMEA (AUD Mn)

000

Valuation Snapshot

MetricValueSource

ASX price 30 Jul 2026

A$0.505 (post-consolidation)

InvestSMART

Pre-consolidation price at Sep 2025 placement

A$0.013 (≈A$0.65 consolidated-equivalent)

InvestSMART

Pre-consolidation price 21 Nov 2025

A$0.009 (≈A$0.45 equivalent)

InvestSMART

Market cap (derived)

≈A$110M

20-F share count × price

Enterprise value (derived)

≈A$73M (market cap less A$37.3M cash)

Derived

P/B (derived)

≈2.6x (A$110M / ≈A$42.5M NTA)

Derived

Analyst coverage

Additional independent research coverage attracted in FY2026 (names/targets not disclosed in sources reviewed)

FY2026 Chairman's letter

Dividends

Never paid; none expected

20-F

Credit ratings

Not rated; no debt

—

Equity raised (AUD Mn)

FY2022

FY2023

Analyst Conclusions

Management guidance: Initiate ATH434 Phase 3 trial activities in MSA by end of CY2026; continue evaluating partnering, licensing and funding alternatives. No consensus revenue/earnings expectations (pre-revenue).

Bull case

  1. The pivotal trial is built around the endpoint on which ATH434 already showed a ~46% relative effect (50 mg, week 52), and the FDA has agreed a single trial plus confirmatory evidence could suffice.

  2. Scarcity value: an oral, Phase 3-ready disease-modifying MSA asset with orphan/Fast Track status and IP to 2045 is attractive to pharma — a licence could fund Phase 3 and re-rate the ~A$73M enterprise value.

  3. Balance sheet (A$37.3M cash + A$3.98M refund, no debt) funds start-up activities without immediate dilution.

Bear case

  1. Single-asset binary risk: MSA trials have failed in Phase 3 before, and Phase 2 effect sizes in small trials frequently shrink.

  2. A global ~200-patient trial will likely require tens of millions more than current cash; absent a partner, further dilutive raises are near-certain (burn already doubled to A$23.4M).

  3. Better-funded competitors (Lundbeck, Teva) could reach the market first or set a higher efficacy bar.

Catalysts / monitorables (next 12 months): Phase 3 initiation (first site activation/first patient); partnering announcement; financing (placement/ATM/licence); FY2027 quarterly burn; additional ex-US regulatory interactions (EMA); publications of Phase 2 data; competitor MSA readouts; Nasdaq compliance after consolidation; inclusion in indices.

Analyst verdict. Alterity has, after nearly three decades, converted the metal-chaperone thesis that Prana pioneered into a genuinely late-stage asset. The 2025 Phase 2 data and the 2026 regulatory sequence — Type C feedback on pharmacology, nonclinical and CMC, then an End-of-Phase 2 meeting aligning on a single pivotal trial — represent the most de-risked position in the company's history. The design agreed with the FDA (about 200 patients, modified UMSARS Part I, 50 mg twice daily) is efficient by neurology standards, and the choice of an endpoint already showing a clinically meaningful effect in Phase 2 is a material advantage. Patent protection to 2045 and orphan exclusivity provide a long commercial runway if successful.

The constraints are capital and concentration. FY2026's A$23.4M loss shows spending has stepped up before the trial has even started; Phase 3 will lift it further. Cash of A$37.3M is adequate for start-up and early enrolment, not for completion. Management's repeated references to pharma discussions suggest a partnership is the preferred route, and the regulatory clarity obtained in mid-2026 is precisely the de-risking event licensors typically wait for. Absent a deal, investors should expect another sizeable raise within roughly 12–18 months.

The next 12 months should be judged on execution (trial initiation on time) and on the quality of funding — a partnership that preserves meaningful economics would be the strongest validation; a deeply discounted equity raise would signal the market's scepticism.


Sources consulted: FY2026 Appendix 4E, Chairman's letter and Form 20-F (via Webull bulletin, 28 Aug 2026); 20-F filing release (31 Aug 2026); Appendix 4E FY2022–FY2025 (ASX; SEC 6-K exhibits); H1 FY2026 6-K (Stock Titan); Q2, Q3, Q4 FY2026 Appendix 4C summaries (InvestSMART, GlobeNewswire/iTiger, Quartr, Midas); Placement releases 10 Feb 2025 and 8 Sep 2025 (ASX, SEC, BioSpace, Biotech Dispatch); Board-change 6-K 21 Nov 2025 (SEC; Stockhead; InvestSMART); Patent release 12 Aug 2026 (InvestSMART); EGM results 29 May 2026; FY2022/FY2024/FY2025 Form 20-F (SEC); Panabee; TheOfficialBoard; Quantisnow.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleSinceBackground / notesSource

Julian Babarczy

Non-Executive Chair

21 Nov 2025

25+ years in finance and investment/funds management; director/chair of several ASX companies

6-K 21 Nov 2025; Stockhead

David Stamler, M.D.

Managing Director & CEO

CEO Jan 2021; MD 21 Nov 2025

Joined May 2017 as CMO/SVP Clinical Development

FY2022 20-F; 6-K Nov 2025

Peter Marks

Non-Executive Director

—

Directorships incl. Noxopharm, Iris Metals, EverGreen Lithium; previously Elsight, Nyrada

FY2025 20-F

Ann Cunningham

Independent Non-Executive Director

Apr 2026

—

Q4 FY2026 4C

Abby Macnish Niven

CFO & Company Secretary

CFO 30 Sep 2024; Co Sec 18 Nov 2024

—

FY2025 20-F

Daniel O. Claassen, M.D.

Chief Medical Advisor

Mar 2026

—

Q3 FY2026 4C

Competitive Landscape

Key Competitors

CompanyAsset / approachPositioning vs Alterity

H. Lundbeck A/S

Amlenetug (anti-alpha-synuclein antibody)

Large-cap sponsor; late-stage MSA program — most direct well-funded rival

Teva Pharmaceutical

Emrusolmin (oligomer modulator, licensed from MODAG)

Big-pharma backed MSA program

Theravance Biopharma

Ampreloxetine (symptomatic, neurogenic orthostatic hypotension in MSA)

Symptomatic, potentially complementary

Ionis / Biogen

Antisense against alpha-synuclein (MSA)

Genetic-medicine approach, intrathecal

Corestem (Korea)

Mesenchymal stem cell therapy for MSA

Regional cell therapy

AC Immune

Alpha-synuclein immunotherapies

Earlier-stage synucleinopathy

Vaxxinity

UB-312 anti-alpha-synuclein vaccine

Early clinical

Inhibikase Therapeutics

Kinase inhibitor programs in synucleinopathies

Small-cap peer

Biohaven

Verdiperstat (failed MSA Phase 3, 2021)

Illustrates late-stage risk

Annovis Bio

Translational inhibitors in neurodegeneration

Adjacent small-cap

Peer Comparison FY2026

MetricAlterityLundbeckTevaTheravance

Revenue

Nil (interest A$1.7M FY2026)

Multi-billion DKK

Multi-billion US$

Commercial royalties/product revenue

MSA stage

Phase 3-ready, oral, disease-modifying

Late-stage antibody

Clinical small molecule

Phase 3 symptomatic

Route

Oral

IV infusion

Oral

Oral

R&D intensity

~100% of spend

Moderate

Low-moderate

High

Recent Developments

--

Company Snapshot

1997

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Positive randomised Phase 2: ~46% relative treatment effect on UMSARS Part I at week 52 (50 mg) (FY2026 Chairman's letter).
  • FDA EOP2 alignment on single ~200-patient pivotal Phase 3 (Jun–Jul 2026).
  • Cash A$37.3M (30 Jun 2026) plus A$3.98M refund; no debt.
  • Fast Track and US/EU Orphan Drug designations (ASX 12 Aug 2026).
  • Composition-of-matter protection to at least 2045.
  • CMC specifications agreed with FDA; registrational GMP batch produced.

Weaknesses

  • Single-asset concentration acknowledged as principal risk (20-F).
  • Net loss up 92.6% to A$23.4M in FY2026.
  • No internal manufacturing or commercial capability (20-F).
  • History of dilution: A$60M raised in 2025 at A$0.011–0.012 pre-consolidation.
  • PFIC status for US holders (FY2026 20-F) deters some US investors.
  • Legacy of failed PBT2 programs in Alzheimer's/Huntington's.

Opportunities

  • Pharma partnership/licence to fund Phase 3 non-dilutively (ongoing discussions, Q3–Q4 FY2026 4Cs).
  • Expansion into Parkinson's disease supported by new patent.
  • Priority review / rare pediatric-type incentives not applicable, but orphan exclusivity (7 yr US, 10 yr EU).
  • Broader US institutional ownership after consolidation.
  • Biomarker leadership (QSM imaging, NfL) via Vanderbilt collaboration.
  • Potential takeover interest given scarcity of late-stage MSA assets.

Threats

  • Phase 3 failure — late-stage MSA has failed before (e.g., verdiperstat).
  • Competitors (Lundbeck, Teva) with superior resources.
  • US drug-pricing reform and MFN pricing (20-F).
  • FDA disruptions/leadership changes (20-F).
  • Nasdaq continued-listing requirements (US$1 ADS minimum bid) (20-F).
  • Financing risk if markets close before Phase 3 enrolment.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2025 (H1)Positive ATH434-202 open-label data in advanced MSASecond Phase 2 supportive dataset
29 Aug 2025FY2025 results: net loss A$12.1M; cash A$33.2MFunded for regulatory phase
8 Sep 2025A$20M strategic placement at A$0.012Strengthened register
Q1 FY2026Continued FDA engagement planningRegulatory
21 Nov 2025Kempler and Meltzer retire; Babarczy Chair; Stamler MDGenerational governance change
31 Dec 2025Cash A$49.2M; quarterly op outflow A$5.28MPeak cash
30 Jan 2026Q2 FY2026 4C; strengthened Phase 2 data; partnering talksStrategy update
Feb 2026H1 FY2026 results: loss A$9.6M (+34%)Spend rising
Mar 2026Positive FDA feedback on clinical pharmacology and nonclinical elementsDe-risking
Mar 2026Daniel Claassen appointed Chief Medical AdvisorClinical leadership
Apr 2026Positive FDA feedback on CMC for Phase 3Manufacturing de-risking
Apr 2026AAN: MuSyCA analysis shows 41% relative treatment effect at week 52Scientific validation
Apr 2026Ann Cunningham joins boardGovernance
Apr 2026Virtual KOL eventInvestor outreach
30 Apr 2026Q3 FY2026 4C: cash A$44.53MFunding
May 2026Three international presentations (ISMRM, MDSANZ, UCL) on mechanismScientific validation
29 May 2026EGM approves 1:50 consolidationCapital structure
Jun 2026Positive EOP2 meeting: single pivotal Phase 3 (~200 pts, mUMSARS Part I, 50 mg BID)Key regulatory milestone
Jul 2026FDA minutes confirm EOP2 alignmentConfirms pathway
Jul 2026A$3.98M R&D tax refund receivedNon-dilutive cash
30 Jul 2026Q4 FY2026 4C: cash A$37.3M; FY op outflow A$22.5MFunding
Aug 2026Canaccord Genuity Growth Conference presentationInvestor outreach
12 Aug 2026US crystalline-form patent to 2045IP extension
28 Aug 2026FY2026 Appendix 4E: loss A$23.4M (+92.6%)Burn rising
31 Aug 2026Form 20-F filed with SECCompliance
Sep 2026Cantor Fitzgerald Global Healthcare Conference presentationInvestor outreach

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Neurodegenerative drug development — revenue rose from AUD 0.3 Mn in FY2024 to AUD 1.7 Mn in FY2026.
Alterity Therapeutics Limited — Revenue by Segment
Series (AUD Mn)FY2024FY2025FY2026
Neurodegenerative drug development — revenue0.30.51.7
Neurodegenerative drug development — net loss-19.1-12.2-23.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.